http://www.medcvinc.com
MedicalCV, Inc. offers healthcare technology for cardiac tissue ablation procedures in open-heart surgery. Its ATRILAZE system is indicated for delivery of laser light to soft tissue, including cardiac tissue during surgical procedures. Indications include the incision, excision, dissection, vaporization, ablation, or coagulation of soft tissues. The company, formerly CV Dynamics, Inc., was founded in 1971 and is based in Inver Grove Heights, Minnesota.
Share Structure
Shares Outstanding: 9.84M
Float: 5.49M
% Held by Insiders4: 39.55%
% Held by Institutions4: 7.30%
MAJOR DIRECT HOLDERS (FORMS 3 & 4)
Holder Shares
ROTH MICHAEL N/A
MILLER PAUL K 1,467,580
MILLENNIUM PARTNERS, L.P. 9,056,800
HAUSER PETER L 4,251,757
MEDCAP PARTNERS LP 847,114
TOP INSTITUTIONAL HOLDERS
Shares % Out Value*
POTOMAC CAPITAL MANAGEMENT, INC. 892,857 9.08 $3,616,070
SEC FILINGS
http://finance.yahoo.com/q/sec?s=MCVI.OB
RECENT HEADLINE
Press Release Source: MedicalCV, Inc.
MedicalCV, Inc. Receives Three Additional Notices of Allowance on Patent Applications for Laser-Based Surgical Ablation Technology Platform
Tuesday May 22, 8:00 am ET
MINNEAPOLIS--(BUSINESS WIRE)--MedicalCV, Inc. (OTCBB:MCVI - News), www.medcvinc.com, announced that the United States Patent and Trademark Office ("USPTO") has issued three additional Notices of Allowance to MedicalCV on patent applications pertaining to various aspects of MedicalCV's proprietary laser-based surgical ablation technology. MedicalCV currently markets both the ATRILAZE(TM) and SOLAR(TM) Surgical Ablation Systems.
"These recent notices represent important additions to our strong patent portfolio of laser-based surgical ablation systems," said Adam L. Berman, MedicalCV's Vice President of Research and Development. "Moving forward, we will continue to focus on applying novel, flexible, fiber-optic technologies to medicine."
"These Notices of Allowance not only serve as an additional validation source for our technology but further demonstrate our commitment to protecting our intellectual property as well," said Marc P. Flores, President and CEO of MedicalCV. "As we go to market, we are confident that these Notices of Allowance place the company in a position of strength as we continue to build shareholder value."
Both the SOLAR(TM) and ATRILAZE(TM) Surgical Ablation Systems were developed from MedicalCV's laser-based technology with the intent to provide surgeons a versatile ablation platform for the creation of lesions in soft and cardiac tissue. The SOLAR(TM) System recently received 510(K) Clearance from the FDA for soft tissue ablation and the ATRILAZE(TM) System has obtained 3 separate 510(K) Clearances for ablation or coagulation of soft tissue, including cardiac tissue. However, the treatment indication for cardiac arrhythmias is specifically excluded for both systems at this time. To date, the company's surgical ablation systems have been used in numerous institutions around the country including Baylor University Medical Center, Northwestern University Medical Center, University of Michigan Medical Center, Baptist Medical Center in San Antonio, Texas, Scottsdale Healthcare - Osborn in Arizona, Banner Good Samaritan Medical Center in Phoenix, and Banner Baywood Heart Hospital in Mesa, Arizona.
Daily Chart
Weekly Chart
